Information Provided By:
Fly News Breaks for February 21, 2018
ABBV
Feb 21, 2018 | 10:05 EDT
After AbbVie reported that one of its two Phase 3 trials of elagolix in patients with uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints, Piper Jaffray analyst Christopher Raymond said it was "hard to quibble with the efficacy data." He expects to see 12-month data from both trials later this year or early next, which would set up for a potential uterine fibroids launch in 2020. Raymond, who said he "would not be shocked" if his revenue estimates in this indication prove conservative, keeps an Overweight rating on AbbVie.
News For ABBV From the Last 2 Days
There are no results for your query ABBV
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.